Description
Age-Related Macular Degeneration (AMD) is a condition that affects the back of the eye called the macula. AMD is described as either dry or wet AMD.
Age-related macular degeneration causes progressive damage to the macula, resulting in gradual loss of central vision. There are two types of AMD, namely, dry (nonexudative or atrophic), and wet (neovascular or exudative). About 80 to 90% of the people with AMD have only the dry type. The market growth is mainly driven by the rising prevalence of AMD in the geriatric population and off-patent of blockbuster drugs.
Age-related macular degeneration is an ocular disease that involves the posterior aspect of the retina called the macula. The wet form of AMD is less frequent but is responsible for 90% of the acute blindness due to AMD.
As per the study published in the Asia-Pacific Journal of Ophthalmology in 2017, the global prevalence of AMD was nearly 8.7%, with the prevalence of early AMD and late AMD being 8.0% and 0.4%, respectively. A marked increase in the prevalence of AMD was found to be higher in patients over 60 years of age. According to the study published in the Clinical Interventions in the Aging Journal in 2017, AMD is a major cause of central visual loss which affects nearly 10% of the people older than 65 years and more than 25% of people older than 75 years. It is also reported that in the US approximately 2 million individuals have advanced AMD and more than 8 million individuals have an intermediate form of the disease. The number is expected to rise by 50% by 2020.
On the other hand, certain factors restraining the growth of the market include the high cost associated with AMD. The current mainstay of treatment for AMD is anti-Vascular Endothelial Growth Factor agents (anti-VEGF) with demonstrated efficacy in improving visual acuity. There are various anti-VEGF drugs available to treat AMD, but three are most commonly used for the condition. Two of these, namely, Lucentis (ranibizumab) and Eylea (aflibercept) are specifically designed and are FDA-approved for the treatment of AMD. The third drug, Avastin (bevacizumab) was originally developed to treat cancer but is commonly used off-label in patients with AMD.
The average cost of AMD treatment with Lucentis is approximately USD 2000, and with Eylea, it is around USD 1800. However, an average AMD treatment cost with Avastin is USD 50. Although Avastin carries a similarly high price tag, as Lucentis and Eylea, when used for colon cancer, in case of eye treatment, it is less expensive because only 1/40th of the drug is being used for each dose.
The global market for age-related macular degeneration is estimated to reach USD 11,186.8 million by 2023, from USD 7,128.4 million in 2017. The market is projected to grow at a CAGR of 7.80%, during the forecast period of 2017 to 2023.
On the basis of type, the market for age-related macular degeneration is segmented into dry age-related macular degeneration and wet age-related macular degeneration. By type, the market for wet age-related macular degeneration accounted for the largest market share in 2017.
On the basis of stages, the market for age-related macular degeneration is segmented into early age-related macular degeneration, intermediate age-related macular degeneration, and late age-related macular degeneration. By stages, the market for intermediate age-related macular degeneration accounted for the largest market share in 2017.
The global age-related macular degeneration market, by age group, is segmented into above 40 years, above 60 years, and above 75 years. By age, the market for above 75 years accounted for the largest market share in 2017.
The global age-related macular degeneration, by diagnosis and treatment type, is segmented into diagnosis and treatment. The treatment segment holds the largest market share in the global age-related macular degeneration market, by diagnosis and treatment.
On the basis of route of administration, the global age-related macular degeneration market is segmented into intravenous, intravitreal, and others. The intravitreal segment dominates the global age-related macular degeneration market.
The global age-related macular degeneration market, on the basis of end-user, is segmented into hospitals and clinics, diagnostic centers, academic research institutes, and others. Hospitals and clinics hold the largest market share in the global age-related macular degeneration market.
Key Players
The key players for the age-related macular degeneration market are F. Hoffmann-La Roche AG, Regeneron Pharmaceutical Inc., Novartis AG, Bayer AG, Santen Pharmaceuticals co, and others.
Study Objectives
• To provide historical and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries
• To provide insights into factors influencing and affecting the market growth
• To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic factors that influence the global age-related macular degeneration market
Target Audience
• Pharmaceutical and Medical Device Industries
• Potential Investors
• Medical Research Institutes
• Key Executive (CEO and COO) and Strategy Growth Manager
• Research Companies
Key Findings
• The major market players in the global age-related macular degeneration market are F. Hoffmann-La Roche AG, Regeneron Pharmaceutical Inc., Novartis AG, Bayer AG, Santen Pharmaceuticals co, and others
• F. Hoffmann-La Roche AG accounted for more than 13.2% share of the global age-related macular degeneration market
• Based on type, the wet age-related macular degeneration segment commanded the largest market share in 2017 and was valued at USD 4,423.5 million in 2017
• Based on stages, the intermediate Age-Related Macular Degeneration (AMD) segment commanded the largest market share in 2017 and was valued at USD 3,224.6 million in 2017
• On the basis of region, the American region is projected to be the fastest growing region, at a CAGR of 7.86% during the forecast period
Regional Analysis
Americas
• North America
o US
o Canada
• South America
Europe
• Western Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Western Europe
• Eastern Europe
Asia-Pacific
o China
o Japan
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific
The Middle East & Africa
• Middle East
• Africa
Table of Contents:
1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 Assumptions & Limitations
3.3.1 Assumptions
3.3.2 Limitations
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Growing geriatric population and increasing prevalence of age-related macular degeneration
5.2.2 Several branded drugs going off patent
5.3 Restraints
5.3.1 High cost associated with AMD
5.3.2 Stringent FDA regulations
5.4 Opportunities
5.4.1 Strong pipeline
5.5 Pipeline Analysis
5.5.1 Brolucizumab 6 mg
5.5.2 NCT01691261
5.5.3 NCT03102138
5.5.4 Lampalizumab
5.5.5 RG7716
5.5.6 Emixustat
5.5.7 Zimura Dry AMD
5.5.8 Zimura Wet AMD
5.5.9 GSK933776
5.5.10 RXI-109
5.5.11 Abicipar Pegol
6 Market Factor Analysis
6.1 Supply Chain Analysis
6.1.1 R&D
6.1.2 Parts Manufacturing
6.1.3 Distribution
6.1.4 Marketing & Sales
6.1.5 Post-Sales Monitoring
6.2 Porter’s Five Forces Analysis
6.2.1 Bargaining Power of Suppliers
6.2.2 Bargaining Power of Buyers
6.2.3 Threat of New Entrants
6.2.4 Threat of Substitutes
6.2.5 Intensity of Rivalry
7 Global Age-Related Macular Degeneration Market, by Type
7.1 Overview
7.1.1 Introduction
7.1.2 Wet Age-Related Macular Degeneration (Wet AMD)
7.1.3 Dry Age-Related Macular Degeneration (Dry AMD)
8 Global Age-Related Macular Degeneration Market, by Stages
8.1 Overview
8.1.1 Introduction
8.1.2 Intermediate stage age-related macular degeneration
8.1.3 Early-stage age-related macular degeneration
8.1.4 Late stage age-related macular degeneration
9 Global Age-Related Macular Degeneration Market, by Age Group
9.1 Overview
9.1.1 Introduction
9.1.2 Above 75 years
9.1.3 Above 60 years
9.1.4 Above 40 years
10 Global Age-Related Macular Degeneration Market, by Diagnosis & Treatment
10.1 Overview
10.1.1 Introduction
10.1.2 Treatment
10.1.3 Diagnosis
11 Global Age-Related Macular Degeneration Market, by Route of Administration
11.1 Overview
11.1.1 Introduction
11.1.2 Intravitreal route of administration
11.1.3 Intravenous route of administration
12 Global Age-Related Macular Degeneration Market, By End-User
12.1 Overview
12.1.1 Introduction
12.1.2 Hospital & Clinics
12.1.3 Diagnostic Centers
12.1.4 Academic research institutes
13 Age-Related Macular Degeneration Market, by Region
13.1 Introduction
13.2 Americas
13.2.1 North America
13.2.1.1 U.S.
13.2.1.2 Canada
13.2.2 South America
13.3 Europe
13.3.1 Western Europe
13.3.1.1 Germany
13.3.1.2 France
13.3.1.3 U.K
13.3.1.4 Italy
13.3.1.5 Spain
13.3.1.6 Rest of Western Europe
13.3.2 Eastern Europe
13.4 Asia Pacific
13.4.1 Japan
13.4.2 China
13.4.3 India
13.4.4 Australia
13.4.5 Republic of Korea
13.4.6 Rest of Asia Pacific
13.5 The Middle East and Africa
13.5.1 Middle East
13.5.2 Africa
14 Competitive Landscape
14.1 Company Market Share Analysis
14.1.1 Introduction
14.2 Key Strategic Analysis
14.2.1 Introduction
15 Company Profiles
15.1 Novartis AG
15.1.1 Company Overview
15.1.2 Financial Overview
15.1.3 Products Offering
15.1.4 Key Developments
15.1.5 SWOT Analysis
15.1.6 Key Strategy
15.2 Pfizer Inc.
15.2.1 Company Overview
15.2.2 Financial Overview
15.2.3 Products Offering
15.2.4 Key Developments
15.2.5 SWOT Analysis
15.2.6 Key Strategy
15.3 F. Hoffmann-La Roche AG
15.3.1 Company Overview
15.3.2 Financial Overview
15.3.3 Products Offering
15.3.4 Key Developments
15.3.5 SWOT Analysis
15.3.6 Key Strategy
15.4 Acucela Inc.
15.4.1 Company Overview:
15.4.2 Financial Overview
15.4.3 Products Offering
15.4.4 Key Developments
15.4.5 SWOT Analysis
15.4.6 Key Strategy
15.5 Ophthotech Corporation
15.5.1 Company Overview
15.5.2 Financial Overview
15.5.3 Products Offering
15.5.4 Key Developments
15.5.5 SWOT Analysis
15.5.6 Key Strategy
15.6 GlaxoSmithKline Plc.
15.6.1 Company Overview
15.6.2 Financial Overview
15.6.3 Products Offering
15.6.4 Key Developments
15.6.5 SWOT Analysis
15.6.6 Key Strategy
15.7 Bayer AG
15.7.1 Company Overview
15.7.2 Financial Overview
15.7.3 Products Offering
15.7.4 Key Developments
15.7.5 SWOT Analysis
15.7.6 Key Strategy
15.8 Rxi Pharmaceuticals, Inc.
15.8.1 Company Overview
15.8.2 Financial Overview
15.8.3 Pipeline Products
15.8.4 Key Developments
15.8.5 SWOT Analysis
15.8.6 Key Strategy
15.9 Regeneron Pharmaceutical Inc.
15.9.1 Company Overview
15.9.2 Financial Overview
15.9.3 Products Offering
15.9.4 Key Developments
15.9.5 SWOT Analysis
15.9.6 Key Strategy
15.1 Alimera Sciences Inc.
15.10.1 Company Overview
15.10.2 Financial Overview
15.10.3 Pipeline Products
15.10.4 Key Developments
15.10.5 SWOT Analysis
15.10.6 Key Strategy
15.11 Santen Pharmaceuticals co.
15.11.1 Company Overview
15.11.2 Financial Overview
15.11.3 Products Offering
15.11.4 SWOT Analysis
15.11.5 Key Developments
15.11.6 Key Strategy
15.12 ALLERGAN
15.12.1 Company Overview
15.12.2 Financial Overview
15.12.3 Products Offering
15.12.4 SWOT Analysis
15.12.5 Key Developments
15.12.6 Key Strategy
15.13 Bausch & Lomb Incorporated
15.13.1 Company Overview
15.13.2 Financial Overview
15.13.3 Products Offering
15.13.4 Key Developments
15.13.5 SWOT Analysis
15.13.6 Key Strategy
16 Appendix
16.1 Discussion Blue Print
